The epithelium in idiopathic pulmonary fibrosis: breaking the barrier

Our plain-English summary of The epithelium in idiopathic pulmonary fibrosis: breaking the barrier, by A. Camelo, R. Dunmore, M.A. Sleeman, et al (Frontiers in Pharmacology, 2014).

The study

• Authors: A. Camelo, R. Dunmore, M.A. Sleeman, D.L. Clarke
• Journal: Frontiers in Pharmacology
• Published: 2014;4:173
• Type of article: Review
• Cited by: 200 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Idiopathic pulmonary fibrosis is a progressive disease of unknown etiology characterized by a dysregulated wound healing response that leads to fatal accumulation of fibroblasts and extracellular matrix (ECM) in the lung, which compromises tissue architecture and lung function capacity. Injury to type II alveolar epithelial cells is thought to be the key event for the initiation of the disease, and so far both genetic factors, such as mutations in telomerase and MUC5B genes as well as environmental components, like cigarette smoking, exposure to asbestos and viral infections have been implicated as potential initiating triggers. The injured epithelium then enters a state of senescence-associated secretory phenotype whereby it produces both pro-inflammatory and pro-fibrotic factors that contribute to the wound healing process in the lung. Immune cells, like macrophages and neutrophils as well as activated myofibroblasts then perpetuate this cascade of epithelial cell apoptosis and proliferation by release of pro-fibrotic transforming growth factor beta and continuous deposition of ECM stiffens the basement membrane, altogether having a deleterious impact on epithelial cell function. In this review, we describe the role of the epithelium as both a physical and immunological barrier between environment and self in the homeostatic versus diseased lung and explore the potential mechanisms of epithelial cell injury and the impact of loss of epithelial cell permeability and function on cytokine production, inflammation, and myofibroblast activation in the fibrotic lung.

In plain English

This article was a review, not an original study. It described published research on the cells lining the lung (the epithelium) in idiopathic pulmonary fibrosis (IPF). IPF is a progressive scarring lung disease of unknown cause, and the review cited a median survival after diagnosis of only 2.5–3.5 years. The review discussed how injury to and death of these lining cells may start and keep driving the scarring. It named genetic factors and environmental exposures, including cigarette smoke, viral infections and asbestos, as possible triggers. Drawing on other researchers' work, it described reactive oxygen species formed after injury from substances such as cigarette smoke, asbestos and bleomycin as able to push lung lining cells into stress and cell death. It also described injury such as asbestos exposure as one possible way of releasing TGF-beta, a signalling protein involved in scarring. The review presented no new data from asbestos-exposed people. It noted that lung transplantation was the only available treatment shown to improve survival. The authors concluded that accumulating evidence suggests the death of alveolar epithelial cells may be the initial trigger of the disease.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: narrative review of published research
• Who was studied: Not applicable: a review of published laboratory, animal and patient research on idiopathic pulmonary fibrosis, not a study of a defined group of people
• Exposure: Asbestos was mentioned only as one of several possible environmental triggers of epithelial injury, alongside cigarette smoke, viral infections and bleomycin. No fiber type was specified.
• Main results:
  • Citing other studies, the review described reactive oxygen species formed as a response to injury from cigarette smoke, asbestos, bleomycin and other agents as able to activate cell stress responses and ultimately cell death (apoptosis) in lung epithelial cells.
  • Citing a 2008 study by Sullivan and colleagues, the review stated that release of active TGF-beta from its stored form can be caused by oxidation, which could be initiated by injury such as asbestos exposure.
  • Citing another source, the review stated that IPF has a median survival after diagnosis of only 2.5–3.5 years.
  • The review stated that lung transplantation was the only currently available treatment for IPF shown to improve survival.
• The authors' conclusion: The authors concluded that accumulating evidence suggests alveolar epithelial cell apoptosis may be the initial trigger of IPF, with both genetic background and environmental exposure contributing.

Topics

Medical terms in this study, explained in our Lexicon: Epithelium, Idiopathic, Pulmonary Fibrosis, Etiology, Fibroblast, Macrophage, Apoptosis, Deposition.

Related studies

• The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis — B.D. Bringardner, C.P. Baran, et al. (2008)
• A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis — J.M. Englert, L.E. Hanford, et al. (2008)
• Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: case-control study — M.J. Abramson, T. Murambadoro, et al. (2020)
• Relative release of interleukin-1 beta and interleukin-1 receptor antagonist by alveolar macrophages. A study in asbestos-induced lung disease, sarcoidosis, and idiopathic pulmonary fibrosis — J.N. Kline, D.A. Schwartz, et al. (1993)
• Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis — K.A. Khan, M.P. Kennedy, et al. (2015)
• Loss of ANT1 Increases Fibrosis and Epithelial Cell Senescence in Idiopathic Pulmonary Fibrosis — J. Sui, J.C. Boatz, et al. (2023)

Browse more research in Frontiers in Pharmacology, or return to medical research.